Genetic and molecular testing of samples from people with blood cancers
Studies stored and new blood or bone marrow samples from people with blood cancers.
Plain-language title generated from the registry record
Registry title: Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
Key facts
- Where
- Parma, ItalySee the site
Where in Italy
- University of ParmaParma, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda Ospedaliero-Universitaria di Parma
- Trial code
- NCT07445984
- Record updated
- 3 March 2026
- Original description
The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.Read full original descriptionShow less
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
The study will be conducted retrospectively and prospectively, using bone marrow (BM) or peripheral blood (PB) samples or biopsies of lymph nodes or tissues with metastatic involvement taken from previously stored samples here at the University Hospital of Parma or taken from patients that need to underwent diagnostic evaluation for a suspect or a defined diagnosis of hematological malignancies collected at the University Hospital of Parma.
Inclusion: Patient aged >1 year old, referred for evaluation to the University Hospital of Parma; Retrospective study: previously patients with hematological malignancies; Prospective study: 1) patients with clinical suspect of hematological malignancies which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc. 2) patients with clinical suspect of relapsed/refractory onco-hematological disorder, which requires a diagnostic assessment using bone marrow aspirate/biopsy or biopsies of tissues with metastatic involvement including lymph nodes, liquor from rachicentesis, tissue aspirate etc. 3) patients that progress in blastic transformation from a chronic condition or suspect of relapsed/refractory hematological disease, which requires a diagnostic assessment using peripheral blood drawn, bone marrow aspirate/biopsy, lymph nodes biopsies or biopsies of tissues with metastatic involvement including liquor from rachicentesis, tissue aspirate etc; Written informed consent. Retrospective study: informed consent will be signed during the first follow-up visit.
Exclusion: Patients who are unable to provide informed consent prior to any procedure for any reason; Age <1 year old.